Company news
Puretech Health Plc (LSE:PRTC) news
Puretech Health Plc news releases on 6ix. Latest, Aug 22, 2024: PRTC Adds Industry Leader to Board of Directors
Press releases — page 3
PRTC Adds Industry Leader to Board of Directors
August 22, 2024
PRTC's Seaport Appoints Global Pharma Exec to BOD
August 13, 2024
PRTC'S Vedanta Expands Leadership Team
July 23, 2024
Completion of Tender Offer & Total Voting Rights
June 24, 2024
Result of Tender Offer
June 24, 2024
Director Declaration
June 20, 2024
PRTC's Seaport Appoints Seasoned Execs to Team
June 18, 2024
Result of Meeting
June 6, 2024
Additional Disclosure Re: Tender Offer
June 4, 2024
PRTC's Akili Enters Into Merger Agreement
May 29, 2024
PRTC's Vedanta Begins Phase 3 of VE303 in C. diff
May 21, 2024
Tender Offer
May 20, 2024
PRTC's Seaport Presents Ph1 and Ph2a SPT-300 Data
May 9, 2024
PRTC's Seaport Announces Board/Team Appointments
May 7, 2024
PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
April 16, 2024
FDA Grants PRTC's LYT-200 Fast Track Designation
April 11, 2024
PRTC Launches Seaport w/ $100M; Leadership Changes
April 9, 2024
$100M Tender Offer
March 19, 2024
$14B Acquisition of PRTC’s Karuna by BMS Completed
March 18, 2024
FDA Grants PRTC's LYT-200 Orphan Drug Designation
March 13, 2024
PRTC to Present at Cowen and Leerink Conferences
February 27, 2024
PRTC: Akili Positive Ph3 & Japan PMDA Submission
February 27, 2024
Transaction in Own Shares
February 8, 2024
PureTech to present at the JP Morgan Conference
January 3, 2024
BMY Acquires PRTC Founded Entity Karuna for $14B
December 22, 2023
PRTC Year End Update & Outlook for 2024
December 20, 2023
New LYT-200 Solid Tumors Data Presented at ESMO-IO
December 7, 2023
PRTC: Karuna's NDA for KarXT Accepted by U.S. FDA
November 29, 2023
Karuna's Blood Pressure Trial of KarXT Successful
November 17, 2023
PRTC Achieves Primary Endpoint in Anxiety Trial
November 14, 2023
PRTC to Present at Upcoming Conferences + Progress
October 17, 2023
New LYT-100 Data from Phase 1 Trials at Conference
October 11, 2023
Vedanta VE202 Ph2 Starts + Fast Track Designation
October 4, 2023
KarXT-invented at PRTC-submitted for FDA Approval
September 28, 2023
PRTC Names Robert Lyne as Chief Portfolio Officer
September 27, 2023
PRTC Gets $11.4M Grant for Ph2 of LYT-300 in FXTAS
August 1, 2023
PureTech Begins Ph2a Trial of LYT-300 for anxiety
June 21, 2023
Akili Releases EndeavorOTC - Adult ADHD Treatment
June 7, 2023
PureTech to Present at Jefferies Healthcare Conf
May 24, 2023
New Sonde Study: Vocal Biomarkers for Respiratory
May 23, 2023
Vedanta Fast Track Designation & Ph2 Data at DDW
May 9, 2023
Akili Trial Results of EndeavorRx in Adults w/ADHD
May 4, 2023
PRTC Final Results & Publication of Annual Report
April 28, 2023
Vedanta Gets $106M+ to Advance Microbiome Pipeline
April 25, 2023
Vedanta Publishes VE303 Phase 2 Results in JAMA
April 17, 2023
PRTC Gets Up To $500M From RPRX For KarXT Royalty
March 23, 2023
Karuna 2nd Successful Ph3 Study in Schizophrenia
March 20, 2023
PureTech to Present at Barclays Healthcare Conf
March 1, 2023
Sonde & MGH Lead Study on Frontotemporal Disorders
February 27, 2023
PRTC Plans Ph2a trials w/ LYT-300 in PPD/Anxiety
February 14, 2023